Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.93 USD
+0.01 (1.22%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $0.93 0.00 (0.41%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SGMO 0.93 +0.01(1.22%)
Will SGMO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SGMO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGMO
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates
SGMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
Other News for SGMO
Biotech Alert: Searches spiking for these stocks today
3 Penny Stocks to Watch Now, 8/8/24
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pennant Group (PNTG), Merus (MRUS) and Sangamo Biosciences (SGMO)
RBC Capital Remains a Hold on Sangamo Biosciences (SGMO)
Sangamo Biosciences: Hold Rating Amid Financial Challenges and Clinical Progress